Nathan G. Dolloff - Concepedia

Author

Nathan G. Dolloff

Penn State Milton S. Hershey Medical Center ORCID

Also Known As

, N G Dolloff, N. Dolloff, N. G. Dolloff, NATHAN DOLLOFF, Nathan Dolloff, Nathan G Dolloff, Nathan G. Dolloff

138

Publications

1.9K

Citations

H-Index

Concepts

All Affiliations

Penn State Milton S. Hershey Medical Center University of Pennsylvania Medical University of South Carolina American Cancer Society Pennsylvania State University

About

Nathan G. Dolloff is an author at Penn State Milton S. Hershey Medical Center specializing in medicine, cell biology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	16	834
2	Health Sciences	2	2	89
3	Engineering	1	1	16
4	Natural Sciences	1	1	24
5	Blood Transplantation	1	1	11

Nathan G. Dolloff

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects Joshua E. Allen, Gabriel Krigsfeld, Patrick A. Mayes, Science Translational Medicine	2013	336
CX3CR1-Fractalkine Expression Regulates Cellular Mechanisms Involved in Adhesion, Migration, and Survival of Human Prostate Cancer Cells Shannon A. Shulby, Nathan G. Dolloff, Mark E. Stearns, Cancer Research Radiation OncologySignaling PathwayCell RegulationChemokine FractalkineProstate Cancer Cells	2004	207
Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells Ravyn M. Thompson, Dominik Dytfeld, Leticia Reyes, Oncotarget	2017	133
CDK1 stabilizes HIF-1α via direct phosphorylation of Ser668 to promote tumor growth Noel A. Warfel, Nathan G. Dolloff, David T. Dicker, Cell Cycle Direct PhosphorylationCancer BiologyTumor BiologySignaling PathwayCell Regulation	2013	111
Beyond the CRAB Symptoms: A Study of Presenting Clinical Manifestations of Multiple Myeloma Giampaolo Talamo, Umar Farooq, Maurizio Zangari, Clinical Lymphoma Myeloma & Leukemia Hematological MalignancyPresenting Clinical ManifestationsCrab SymptomsHematologyPathology	2010	83
Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model Holly A.F. Stessman, Linda B. Baughn, Aaron L. Sarver, Molecular Cancer Therapeutics Hematological MalignancyHdac InhibitorsMouse Myeloma ModelMedicineMalignant Blood Disorder	2013	78
Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity Xiaoyang Li, Yuqi Jiang, Yuri K. Peterson, Journal of Medicinal Chemistry	2020	68
Bone-metastatic potential of human prostate cancer cells correlates with Akt/PKB activation by α platelet-derived growth factor receptor Nathan G. Dolloff, Shannon S. Shulby, Autumn Nelson, Oncogene Bone-metastatic PotentialUrologyAkt/pkb ActivationReceptor Tyrosine KinaseProstatic Disease	2005	67
The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth, and chemosensitivity under hypoxic conditions Elizabeth Matthew, Lori S. Hart, Aristotelis Astrinidis, Cell Cycle	2009	65
Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab Lori S. Hart, Nathan G. Dolloff, David T. Dicker, Cell Cycle	2011	60

Page 1